Microsatellite stability results in colon cancer
Part of Cancer, Digestive system clinical trials.
This study looks at a specific genetic feature called microsatellite stability in colon cancer. It may help doctors understand which treatments work best for different patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove colon cancer with the goal of a cure.
- Surgery was done between June 1, 2025, and May 31, 2026.
- The surgery was at a center that does more than 30 colon cancer surgeries per year.
- You had tests to check the MMR proteins or MSI status on a sample from your tumor.
- You have signed a consent form allowing use of your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying people with a specific type of advanced colorectal cancer (MSI-high/dMMR) who are starting immunotherapy with pembrolizumab. The goal is to find out which markers in the tumor might predict whether the treatment works well.
This trial studies whether an at-home stool DNA test (Mt-sDNA) can safely and usefully monitor people after colon or rectal cancer treatment. It’s mainly about whether the test is practical and helpful during routine follow-up.
This study tests if matching treatments to your tumor's genetic markers can help slow down metastatic colorectal cancer. You'll get a biopsy and blood draw to guide your therapy.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
This study looks at tumor test results and medical history to estimate your risk of the cancer coming back or spreading after early-stage colorectal cancer surgery. It may help doctors predict who needs closer follow-up in the future.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.